Published online Sep 15, 2019. doi: 10.4251/wjgo.v11.i9.686
Peer-review started: March 18, 2019
First decision: June 5, 2019
Revised: July 5, 2019
Accepted: August 19, 2019
Article in press: August 19, 2019
Published online: September 15, 2019
Processing time: 181 Days and 18.6 Hours
Core tip: Tumor angiogenesis in gastric cancer (GC) and antiangiogenic therapies for GC, including information from their preclinical and/or application to clinical trials, are discussed. The antiangiogenic strategies for advanced GC include decreasing the expression of proangiogenic ligands and their receptors, increasing the level of angiogenic inhibitors, and directly targeting the inner walls of endothelial cells. Here, the antiangiogenic strategies mainly focus on decreasing the expression of vascular endothelial growth factor-mediated pathway constituents for advanced GC in phase III clinical trials. Thus, this review provides a brief description of various tumor angiogenic factors for the purposes of diagnosis, prognosis and therapeutics and describes the antiangiogenic agents that are currently being investigated in preclinical and phase III clinical trials. Hopefully, according to the molecular mechanism of tumor angiogenesis, we highlight the accuracy of the diagnosis and prognosis and the selection of the most appropriate therapy for GC patients.